Skip to main content

Cancer Immunology, Immunotherapy

Ausgabe 6/2024

Inhalt (20 Artikel)

Open Access Research

CD200 is overexpressed in the pancreatic tumor microenvironment and predictive of overall survival

Jessica Wedig, Shrina Jasani, Debasmita Mukherjee, Hannah Lathrop, Priya Matreja, Timothy Pfau, Liliana D’Alesio, Abigail Guenther, Lexie Fenn, Morgan Kaiser, Molly A. Torok, Jake McGue, Gina M. Sizemore, Anne M. Noonan, Mary E. Dillhoff, Bradley W. Blaser, Timothy L. Frankel, Stacey Culp, Phil A. Hart, Zobeida Cruz-Monserrate, Thomas A. Mace

Open Access Research

Integrating bulk and single-cell sequencing data to construct a Scissor+ dendritic cells prognostic model for predicting prognosis and immune responses in ESCC

Maosheng Cheng, Jianqi Xiong, Qianwen Liu, Caihua Zhang, Kang Li, Xinyuan Wang, Shuang Chen

Open Access Research

Incorporating IL7 receptor alpha signaling in the endodomain of B7H3-targeting chimeric antigen receptor T cells mediates antitumor activity in glioblastoma

Nithidol Sakunrangsit, Nattarika Khuisangeam, Thananya Inthanachai, Varalee Yodsurang, Pasrawin Taechawattananant, Koramit Suppipat, Supannikar Tawinwung

Open Access Research

T-cell subsets and cytokines are indicative of neoadjuvant chemoimmunotherapy responses in NSCLC

Ling Yi, Ziwei Xu, Tianyu Ma, Chong Wang, Panjian Wei, Bo Xiao, Hongtao Zhang, Nanying Che, Zhidong Liu, Yi Han

Open Access Research

Comparative performance of scFv-based anti-BCMA CAR formats for improved T cell therapy in multiple myeloma

Sophia Stock, Luisa Fertig, Adrian Gottschlich, Janina Dörr, Florian Märkl, Lina Majed, Vivien D. Menkhoff, Ruth Grünmeier, Kai Rejeski, David M. Cordas dos Santos, Sebastian Theurich, Michael von Bergwelt-Baildon, Stefan Endres, Marion Subklewe, Sebastian Kobold

Open Access Research

Expansion of tumor-infiltrating lymphocytes from head and neck squamous cell carcinoma to assess the potential of adoptive cell therapy

Sangjoon Choi, Mofazzal Hossain, Hyun Lee, Jina Baek, Hye Seon Park, Chae-Lyul Lim, DoYeon Han, Taehyun Park, Jong Hyeok Kim, Gyungyub Gong, Mi-Na Kweon, Hee Jin Lee

Open Access Research

TLR5 agonist in combination with anti-PD-1 treatment enhances anti-tumor effect through M1/M2 macrophage polarization shift and CD8+ T cell priming

Junseok Lee, Keon-Il Im, Sojin Gil, Hyemin Na, Gi-June Min, Nayoun Kim, Seok-Goo Cho

Open Access Research

Intratumor injection of BCG Ag85A high-affinity peptides enhanced anti-tumor efficacy in PPD-positive melanoma

Lanqun Qin, Guiying Zhang, Yirong Wu, Yueling Yang, Zhengyun Zou

Open Access Research

Associations of granulocyte colony-stimulating factor with toxicities and efficacy of chimeric antigen receptor T-cell therapy in relapsed or refractory B-cell acute lymphoblastic leukemia

Sha Ma, Ying Wang, Kunming Qi, Wenyi Lu, Yuekun Qi, Jiang Cao, Mingshan Niu, Depeng Li, Wei Sang, Zhiling Yan, Feng Zhu, Hai Cheng, Zhenyu Li, Mingfeng Zhao, Kailin Xu

Open Access Research

Global real-world experiences with pembrolizumab in advanced urothelial carcinoma after platinum-based chemotherapy: the ARON-2 study

Francesco Massari, Matteo Santoni, Hideki Takeshita, Yohei Okada, Jose Carlos Tapia, Umberto Basso, Marco Maruzzo, Sarah Scagliarini, Thomas Büttner, Giuseppe Fornarini, Zin W. Myint, Luca Galli, Vinicius Carrera Souza, Renate Pichler, Ugo De Giorgi, Nathalia Gandur, Elaine T. Lam, Danielle Gilbert, Lazar Popovic, Enrique Grande, Giulia Mammone, Rossana Berardi, Simon J. Crabb, Robert Kemp, Javier Molina-Cerrillo, Marcelo Freitas, Murilo Luz, Roberto Iacovelli, Fabio Calabrò, Deniz Tural, Francesco Atzori, Zsófia Küronya, Rita Chiari, Saul Campos, Orazio Caffo, André P. Fay, Jakub Kucharz, Paolo Andrea Zucali, José Augusto Rinck, Annalisa Zeppellini, Diogo Assed Bastos, Gaetano Aurilio, Augusto Mota, Karine Trindade, Cinzia Ortega, Juan Pablo Sade, Mimma Rizzo, Ondřej Fiala, Nuno Vau, Patrizia Giannatempo, Allan Barillas, Fernando Sabino M. Monteiro, Breno Dauster, Alessia Mennitto, Lucas Nogueira, Roni de Carvalho Fernandes, Emmanuel Seront, Luís Garcia Aceituno, Francesco Grillone, Hernan Javier Cutuli, Mauricio Fernandez, Maria Bassanelli, Ray Manneh Kopp, Giandomenico Roviello, Halima Abahssain, Giuseppe Procopio, Michele Milella, Jindrich Kopecky, Angelo Martignetti, Carlo Messina, Manuel Caitano, Eva Inman, Ravindran Kanesvaran, Daniel Herchhorn, Daniele Santini, Aristotelis Bamias, Renato Bisonni, Alessandra Mosca, Franco Morelli, Fernando Maluf, Andrey Soares, Fernando Nunes, Alvaro Pinto, Anca Zgura, Lorena Incorvaia, Jawaher Ansari, Ignacio Ortego Zabalza, Johannes Landmesser, Alessandro Rizzo, Veronica Mollica, Andrea Marchetti, Matteo Rosellini, Giulia Sorgentoni, Nicola Battelli, Sebastiano Buti, Camillo Porta, Joaquim Bellmunt

Open Access Research

A phase I trial of autologous RAK cell immunotherapy in metastatic renal cell carcinoma

Jing Xu, Wen Zhang, Jinlian Tong, Caixia Liu, Qiaohui Zhang, Liren Cao, Jiangyong Yu, Aiping Zhou, Jie Ma

Open Access Research

A2AR-mediated CXCL5 upregulation on macrophages promotes NSCLC progression via NETosis

Qingyang Lei, Shanshan Zhen, Lei Zhang, Qitai Zhao, Li Yang, Yi Zhang

Open Access Research

Synergistic immunomodulatory effect of synbiotics pre- and postoperative resection of pancreatic ductal adenocarcinoma: a randomized controlled study

Sara Maher, Hesham A. Elmeligy, Tarek Aboushousha, Noha Said Helal, Yousra Ossama, Mahmoud Rady, Ahmed Mohamed A. Hassan, Manal Kamel

Open Access Research

Interleukin 33 supports squamous cell carcinoma growth via a dual effect on tumour proliferation, migration and invasion, and T cell activation

Graziela Perri, Vanessa Garcia Vilas Boas, Maria Renata Sales Nogueira, Edgard José Franco Mello Júnior, Ana Lucia Coelho, Edwin M. Posadas, Cory Hogaboam, Karen A Cavassani, Ana Paula Campanelli

Open Access Research

Clonal expansion of shared T cell receptors reveals the existence of immune commonality among different lesions of synchronous multiple primary lung cancer

Yadong Wang, Zhicheng Huang, Bowen Li, Jianchao Xue, Chao Guo, Zhongxing Bing, Zhibo Zheng, Yang Song, Yuan Xu, Guanghua Huang, Haochen Li, Xiaoqing Yu, Yankai Xia, Ruirui Li, Xiaoyan Si, Li Zhang, Ji Li, Lan Song, Yuanyuan Xiong, Dejian Gu, Mengmeng Song, Zhipeng Zhou, Rongrong Chen, Zhe Feng, Zhixin Bie, Xiaoguang Li, Huaxia Yang, Shanqing Li, Naixin Liang

Open Access Research

New genetic insights into immunotherapy outcomes in gastric cancer via single-cell RNA sequencing and random forest model

Dajun Yu, Jie Yang, BinBin Wang, Zhixiang Li, Kai Wang, Jing Li, Chao Zhu

Open Access Research

Neutrophil-activating secretome characterizes palbociclib-induced senescence of breast cancer cells

Gabriele Favaretto, Marianna Nicoletta Rossi, Lorenzo Cuollo, Mattia Laffranchi, Manuela Cervelli, Alessandra Soriani, Silvano Sozzani, Angela Santoni, Fabrizio Antonangeli

Open Access Research

Expression patterns of novel immunotherapy targets in intermediate- and high-grade lung neuroendocrine neoplasms

Bence Ferencz, Klára Török, Orsolya Pipek, János Fillinger, Kristóf Csende, András Lantos, Radoslava Černeková, Marcel Mitták, Jozef Škarda, Patricie Delongová, Evelyn Megyesfalvi, Karin Schelch, Christian Lang, Anna Solta, Kristiina Boettiger, Luka Brcic, Jörg Lindenmann, Ferenc Rényi-Vámos, Clemens Aigner, Judit Berta, Zsolt Megyesfalvi, Balázs Döme

15% bedauern gewählte Blasenkrebs-Therapie

29.05.2024 Urothelkarzinom Nachrichten

Ob Patienten und Patientinnen mit neu diagnostiziertem Blasenkrebs ein Jahr später Bedauern über die Therapieentscheidung empfinden, wird einer Studie aus England zufolge von der Radikalität und dem Erfolg des Eingriffs beeinflusst.

Erhöhtes Risiko fürs Herz unter Checkpointhemmer-Therapie

28.05.2024 Nebenwirkungen der Krebstherapie Nachrichten

Kardiotoxische Nebenwirkungen einer Therapie mit Immuncheckpointhemmern mögen selten sein – wenn sie aber auftreten, wird es für Patienten oft lebensgefährlich. Voruntersuchung und Monitoring sind daher obligat.

Costims – das nächste heiße Ding in der Krebstherapie?

28.05.2024 Onkologische Immuntherapie Nachrichten

„Kalte“ Tumoren werden heiß – CD28-kostimulatorische Antikörper sollen dies ermöglichen. Am besten könnten diese in Kombination mit BiTEs und Checkpointhemmern wirken. Erste klinische Studien laufen bereits.

Perioperative Checkpointhemmer-Therapie verbessert NSCLC-Prognose

28.05.2024 NSCLC Nachrichten

Eine perioperative Therapie mit Nivolumab reduziert das Risiko für Rezidive und Todesfälle bei operablem NSCLC im Vergleich zu einer alleinigen neoadjuvanten Chemotherapie um über 40%. Darauf deuten die Resultate der Phase-3-Studie CheckMate 77T.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.